Option Care Health (NASDAQ:OPCH) Price Target Raised to $38.00

Option Care Health (NASDAQ:OPCH) had its price target raised by Morgan Stanley from $35.00 to $38.00 in a research report report published on Tuesday,Benzinga reports. Morgan Stanley currently has an overweight rating on the stock.

A number of other brokerages also recently issued reports on OPCH. Cowen started coverage on Option Care Health in a research note on Thursday, October 2nd. They set a “hold” rating for the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Option Care Health in a research report on Monday, December 29th. Bank of America increased their price objective on shares of Option Care Health from $32.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Jefferies Financial Group restated a “buy” rating and set a $37.00 target price on shares of Option Care Health in a research note on Tuesday. Finally, Citigroup reiterated an “outperform” rating on shares of Option Care Health in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $37.17.

Option Care Health Price Performance

NASDAQ OPCH opened at $36.11 on Tuesday. The business’s fifty day moving average is $31.33 and its 200 day moving average is $29.51. Option Care Health has a fifty-two week low of $24.24 and a fifty-two week high of $36.18. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.05 and a current ratio of 1.56. The company has a market capitalization of $5.73 billion, a PE ratio of 28.66, a price-to-earnings-growth ratio of 2.12 and a beta of 0.80.

Insiders Place Their Bets

In related news, Director Harry M. Jansen Kraemer, Jr. bought 38,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was bought at an average cost of $25.98 per share, with a total value of $987,240.00. Following the completion of the purchase, the director owned 413,390 shares of the company’s stock, valued at approximately $10,739,872.20. The trade was a 10.12% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.64% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. USA Financial Formulas bought a new stake in shares of Option Care Health in the second quarter worth about $26,000. Cornerstone Planning Group LLC grew its holdings in Option Care Health by 7,621.4% during the 3rd quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock valued at $30,000 after buying an additional 1,067 shares in the last quarter. Advisory Services Network LLC bought a new stake in Option Care Health in the 3rd quarter worth approximately $35,000. McIlrath & Eck LLC bought a new stake in Option Care Health in the 2nd quarter worth approximately $37,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Option Care Health during the 3rd quarter worth approximately $38,000. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.